

New REAL Space Navigator Breaks Billion Compound Barrier

Enamine and BioSolveIT collaboration exceeds expectations to deliver 3.8bn new compounds on demand

Kiev, Ukraine, and Sankt Augustin, Germany, 04 June 2018. Enamine Ltd., a leading compound supplier and BioSolveIT GmbH, a premium provider of drug discovery software, today announced the availability of the next generation of REAL Space Navigator, an efficient search tool within the world's largest purchasable chemical space. Originally launched in February this year, Version 2 of REAL Space Navigator now offers 'search and find' access to an incredible 3.8 billion small molecular weight compounds ready for purchase.

Searching databases of commercially available compounds is a standard approach to advance hit compounds. However, the global stock of screening compounds has already been largely explored, making the identification of new and promising lead molecules difficult and the need for fast access to novel compounds increasingly necessary.

REAL Space Navigator efficiently assembles synthetically feasible molecules based on their similarity to the query molecule using BioSolveIT's unique software technology. This smart approach allows researchers to explore chemical space beyond the capacity of current, conventional search methods.

The next generation of REAL Space Navigator was developed by adding new transformations and building blocks to increase the readily accessible (REAL) compound space and streamlining the software to further speed up access to the giant virtual catalog delivering results within just a few minutes on a standard PC.

Michael Bossert, Head of Strategic Alliances at Enamine commented: "The vast size and speed of development of the search space has exceeded our own expectations and is game changing in terms of access to novel molecules and associated IP value. With almost 4bn compounds to pick from and stunning speed of synthesis within three weeks from order, we have opened the door to a new way of drug discovery with unprecedented cycle times. The immediate uptake by our clients highlights that we are really addressing an as yet unmet need."

Dr. Christian Lemmen, CEO at BioSolvelT, added: "REAL Space Navigator Version 2 not only breaks the nine-digit barrier, but now enters spaces that may not even be enumerated, let alone mined, by conventional methods. The user experience is unique. Searches which are 100% secure behind the firewall complete within minutes, tapping into a universe of possibilities to generate novel therapeutics".

Enamine and BioSolveIT will be presenting the results of their successful collaboration at EFMC-ISMC 2018 conference in Ljubljana, Slovenia - September 2-6, 2018. For further information on REAL Space Navigator, visit: www.biosolveit.de/REALSpaceNavigator.

Notes to Editors



For a high-resolution image, please contact sarah.jeffery@zymecommunications.com

Contacts

Enamine

Michael Bossert Head of Strategic Alliances

Email: m.bossert@enamine.net Phone: +38 044 537 32 18

BioSolveIT

Dr. Marcus Gastreich
Director Application Science
Email: contact@biosolveit.com
Phone: +49 2241 25 25 0

Media enquiries

Sarah Jeffery

Zyme Communications

Email: sarah.jeffery@zymecommunications.com

Phone: +44 7771 730919

About Enamine Ltd. www.enamine.net

Established in Kiev, Ukraine in 1991, Enamine is a chemical company producing building blocks and screening libraries of world reputation. The major asset of the company is the world's largest collection of building blocks: 150,000 in stock with 2,000 additions synthesized each month. These research functionalized compounds provide a significant competitive advantage to the company in supplying custom compound libraries particularly in the frame of medicinal chemistry collaborations or compound collection enhancement programs. Enamine's REAL (readily accessible) concept is based on the careful and knowledge-guided enumeration and selection of compounds that can be confidently produced from the stock building blocks using over 160 validated reaction procedures.

About BioSolveIT GmbH. www.biosolveit.com

BioSolveIT is a global medicinal chemistry informatics and services company. The company is highly renowned for its superior custom software solutions for affinity estimation, structure-based design, docking, flexible molecular alignment, database searching, library design, and analysis. BioSolveIT's visual and fast computational technologies hold several world records and have a proven track record in helping to innovate pharmaceutical research in almost all the big pharma, amongst them AstraZeneca, F.A. Hoffmann-La Roche, BASF, Bayer, Boehringer-Ingelheim, GSK, Novartis, Zealand Pharma, Pfizer, Sanofi, and many others. BioSolveIT is based in Sankt Augustin, Germany, with a support and sales office in Seattle, USA, and several distribution partner offices in Japan, China, and India.